CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...

Delhi, April 04, 2025 (GLOBE NEWSWIRE) -- Over the last two decades, immunotherapy has transformed treatment strategies across various medical fields. The effectiveness of monoclonal antibodies in ...

The "Trispecific Antibodies Clinical Trials, Fast Track Status, Technology Platforms & Market Opportunity Outlook 2025" report has been added to ResearchAndMarkets.com's offering. The trispecific ...

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds ...

The blueprint in the domain of immunotherapy has perceived futuristic with the advent of antibody founded therapy, like monospecific and bispecific antibodies, in the past decenniums. The ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Sham Mailankody, MBBS, discusses results from a first-in-human study of JNJ-5322, a ...

Please provide your email address to receive an email when new articles are posted on . EB-105 has three major moieties that target VEGF-A, VEGF-B, placental growth factor, angiopoietin-2 and ...

A panelist discusses the latest advancements presented at ASCO 2025, highlighting talquetamab’s pivotal trial in relapsed/refractory multiple myeloma that demonstrated high response rates and longer ...

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...

SAN FRANCISCO and SUZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, next-generation trispecific antibodies are yielding high response rates in ...

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate ...